Conditions: HIV Infections
Keywords: HIV Prevention Non-occupational post-exposure prophylaxis HIV seronegativity
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 100
Healthy volunteers: yes

Brief summary:
This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.

Detailed description:
This study will evaluate a three drug regimen in the form of two pills which will be taken for 28 days for the prevention of HIV infection. Two drugs are combined in an FDA-approved pill called TRUVADA, containing the HIV medications, tenofovir disoproxil fumarate 300mg and emtricitabine 200mg, taken as one pill once a day. The third drug is a new formulation, raltegravir 400mg pill taken twice a day.

Arms:
arm 1: TRUVADA

Interventions: intervention 1: TRUVADA + Raltegravir
Intervention descriptions: intervention 1: TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg

Protocol document: